NEW YORKNew data suggests that granisetron (Kytril) can effectively
prevents postoperative nausea and vomiting at doses as low as 0.1 mg. Robert
D’Angelo, MD, Department of Anesthesiology, Wake Forest University, Baptist
Medical Center, presented the study results at the 56th Annual Post Graduate
Assembly in Anesthesiology.
Granisetron is a selective, 5-hydroxy-tryptamine type 3 (5-HT3) receptor
antagonist class of antiemetic. It is approved for intravenous use to prevent
and treat postoperative nausea and vomiting at a dosage of 1 mg, and is also
approved for the prevention of chemotherapy- and radiation-induced nausea and
In this multicenter, randomized, double-blind, dose-ranging pilot study,
121 patients undergoing abdominal hysterectomy requiring general anesthesia
received a single granisetron dose intravenously. The agent proved more
effective than placebo at doses of 0.1 mg, 0.2 mg, and 0.3 mg, and was
similar to the efficacy of other 5-HT3-receptor antagonists.
No Vomiting in More Than 90%
The percentages of patients with no vomiting up to 6 hours after drug
administration were 94%, 96%, 91%, and 77% for granisetron 0.1 mg, 0.2 mg,
0.3 mg, and placebo, respectively. The percentages of patients with total
control (no vomiting, no moderate-to-severe nausea, and no use of rescue
medication over 0 to 6 hours) were 65%, 56%, 67%, and 33%, respectively.